Related Experiment Video

Updated: May 13, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Screening of liver-targeted drugs

Yutaka Midorikawa1, Yasuyuki Sugiyama, Hiroyuki Aburatani

  • 1Teikyo University School of Medicine University Hospital, Department of Surgery, 3-8-3 Mizonokuchi, Takatsu-ku, Kawasaki 213-8507, Japan +81 44 844 3333 ; +81 44 844 3222 ; mido-tky@umin.ac.jp.

Expert Opinion on Drug Discovery
|March 20, 2013
PubMed
Abstract

Insights

Microarray technology aids in discovering new therapeutic targets for liver cancer by analyzing genetic changes. This approach helps identify and prioritize genes for effective gene target therapy.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Cancer is fundamentally a genetic disease driven by accumulating genetic alterations in somatic cells.
  • Targeting oncogenes and reactivating tumor suppressor genes offers significant therapeutic potential for cancer patients.

Purpose of the Study:

  • To explore the utility of microarray technology in identifying novel molecular targets for hepatocellular carcinoma (liver cancer).
  • To review and discuss various microarray techniques for screening liver cancer-specific target genes.

Main Methods:

  • Discussion of diverse microarray technologies, including gene expression arrays, copy number analysis, proteomic profiling, and whole-genome epigenetic aberration analysis.
  • Application of these technologies for the identification and prioritization of therapeutic target genes in liver cancer.

Main Results:

  • Microarray analysis has successfully identified candidate genes that influence cell growth in hepatocellular carcinoma.
  • Prioritization of these genes serves as a basis for developing targeted therapies.

Conclusions:

  • Microarray technology represents a powerful tool for therapeutic target discovery in liver cancer.
  • Recent innovations in this field are advancing the development of gene target therapies, including promising results with monoclonal antibodies.

More Related Videos

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes09:44

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes

Published on: March 3, 2015

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
Hepatic Drug Clearance: Effect of Protein Binding01:09

Hepatic Drug Clearance: Effect of Protein Binding

Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...